AlphaSense Expands Life Sciences Platform with Clinical Trial and Drug Data Integration — ALPHASENSE, INC.

Event summary

AlphaSense launched Clinical Trial and Drug Data on September 15, 2026, integrating clinical, regulatory, and scientific reference data into its AI platform.
The new capability allows Life Sciences professionals to access U.S., E.U., and China market data, including regulatory approvals, trial registries, drug labels, and patents.
AlphaSense's SuperAnalyst AI agent can now handle multi-step research tasks like continuous trial monitoring and competitive landscaping.
The platform is used by 92% of the world's 50 largest pharmaceutical companies, including Biogen, AstraZeneca, Pfizer, and Merck.

The big picture

AlphaSense's expansion into clinical trial and drug data addresses a critical gap in the Life Sciences industry, where 78% of leaders lack confidence in their AI governance. By unifying clinical, regulatory, and market intelligence data, AlphaSense aims to streamline decision-making for pharmaceutical companies and investors, leveraging its existing customer base of 92% of the top 50 pharma firms. This move underscores the growing importance of AI in navigating complex, evidence-driven industries.

What we're watching

AI Adoption: How AlphaSense's AI integration will affect the pace of AI adoption in highly regulated Life Sciences environments.
Regulatory Compliance: Whether AlphaSense can sustain its growth by maintaining rigorous traceability and governance in AI-generated outputs.
Market Differentiation: The pace at which competitors will respond with similar AI-powered clinical and regulatory data solutions.